XML 63 R49.htm IDEA: XBRL DOCUMENT v3.25.0.1
Prepaid and Other Current Assets - Summary of Prepaid Assets and Other Current Assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Prepaid Expense and Other Assets, Current [Abstract]    
Down payments for inventory $ 1,080 $ 16,296
Prepaid research and development 7,780 13,931
Other prepaid assets 9,508 8,593
Total prepaid assets 18,368 38,820
Royalties receivable 4,525 3,054
Receivable from collaboration agreement [1] 2,272 15,000
Deposits and Other Current Assets 4,847 4,354
Total other current assets $ 11,644 $ 22,408
[1] In January 2024 the Company waived the remaining reimbursement payment of $15.0 million in connection with the decision to discontinue the cold agglutinin disease (“CAD”) program. As the reimbursement was related to development costs under the Sobi collaboration agreement, this amount was recorded to research and development expense in the consolidated statements of operations for the period ended December 31, 2024.